Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler®, an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive pulmonary disease (COPD). In this formulation, budesonide acts as an anti-inflammatory agent and formoterol acts as a long-acting bronchodilator. The marketing authorisation covers two strengths (budesonide 160 µg / formoterol 4.5 µg and budesonide 320 µg / formoterol 9 µg) for the treatment of asthma and COPD in patients above 12 years.
Help employers find you! Check out all the jobs and post your resume.
